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Abstract
Syndecan-1 (SDC1), with a variable ectodomain carrying heparan sulphate (HS) chains between different Syndecans, participates in many steps
of inflammatory responses. In the process of proteolysis, the HS chains of the complete extracellular domain can be shed from the cell surface,
by which they can mediate most of SDC1’s function. However, the exact impact on SDC1 which anchored on the cell surface has not been
clearly reported. In our study, we established the models by transfection with the cleavable resistant SDC1 mutant plasmid, in which SDC1
shedding can be suppressed during stimulation. Role of membrane SDC1 in inflammatory pathway, pro-inflammatory cytokine secretion as well
as neutrophil transmigration, and how suppressing its shedding will benefit colitis were further investigated. We found that the patients suffered
ulcerative colitis had high serum SDC1 levels,presented with increased levels of P65, tumour necrosis factor alpha (TNF-a) and IL-1b and
higher circulating neutrophils. NF-jB pathway was activated, and secretion of TNF-a, interleukin-1beta (IL-1b), IL-6 and IL-8 were increased
upon lipopolysaccharide stimuli in intestinal epithelial cells. Syndecan-1, via its anchored ectodomain, significantly lessened these up-regulation
extents. It also functioned in inhibiting transmigration of neutrophils by decreasing CXCL-1 secretion. Moreover, SDC1 ameliorated colitis activ-
ity and improved histological disturbances of colon in mice. Taken together, we conclude that suppression of SDC1 shedding from intestinal
epithelial cells relieves severity of intestinal inflammation and neutrophil transmigration by inactivating key inflammatory regulators NF-jB, and
down-regulating pro-inflammatory cytokine expressions. These indicated that compenstion and shedding suppression of cytomembrane SDC1
might be the optional therapy for intestinal inflammation.
Keywords: ectodomain shedding intestinal inflammation NF-jB pathway neutrophil transmigration pro-inflammatory
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Introduction
Ulcerative colitis (UC) is a worldwide, chronic, idiopathic and inflam-
matory disease of the rectal and colonic mucosa. A combination of
environmental factors and genetic predisposition seems to cause the
disease, but to date, the definitive mechanism is still unknown [1].
Although a variety of endoscopic, radiological and histological criteria
are recommended, the difficulties in differential diagnosis and easy
recurrence of UC are always challenging [2].
Syndecan-1 (CD138, SDC1), a member of the syndecan family of
heparan sulphate (HS) proteoglycans, is predominantly expressed on
the basolateral membrane of epithelial cells. Syndecan-1 is mainly
identified with a long variable ectodomain between different Syndecan
members, a short conserved cytoplasmic domain and a transmem-
brane domain [3]. The ectodomain of SDC1 carries heparin sulphate
chains which acts as a ligand-binding mediate for most of its function
[4]. Through the HS chain, SDC1 can bind a variety of molecules,
including cytokines, chemotactic factors, extracellular matrix
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components and even heparin-binding proteins on the bacterial sur-
face. Thereby, it plays critical roles in matrix remodelling, tissue
repair, regulation of immune function and resolution of inflammation
[5, 6].
Recently, studies have demonstrated that SDC1 participates in the
composition of tight junction and maintains the function of the
mucosa barrier. Syndecan-1 could restore the dysfunction of ZO-1
and occludin in cell monolayers by activating Stat3, maintain the
epithelial integrity, protect enterocytes during interactions with bacte-
ria and lessen epithelial permeability [7]. The extracellular domain of
SDC1, replete with the HS chains, can be proteolytically released from
the cell surface by a process known as ectodomain shedding [8]. This
process is activated in response to injury or infection, and occurs as
a part of the host’s regulated responses to inflammation, microbial
pathogenesis and wound healing [9]. For example, in injured mouse
corneas, SDC1 shedding is induced by Staphylococcus aureus viru-
lence factors. And inhibition of shedding attenuates bacterial virulence
[10]. In acute lung injury mouse model, knockout of matrix metallo-
proteinase 7 (a protein that functions in defence, repair and inflamma-
tion) resulted in a lack of shed SDC1 in the alveolar fluid, and
confining neutrophils in the interstitium of injured lungs [11]. More-
over, SDC1 also has a protective effect during experimental colitis.
Syndecan-1-null mice showed a significantly increased lethality,
impaired mucosal healing and prolonged recruitment of inflammatory
cells; while treatments with functional SDC1 ectodomain analogue
significantly improved the symptoms [12]. Therefore, SDC1 plays
critical roles in the resolution of inflammation. However, the precise
mechanism is not known clearly enough.
Neutrophil transmigration and accumulation in luminal spaces is a
hallmark of mucosal inflammation. Neutrophils migrate out of the cir-
culation, across both endothelial and epithelial barriers in acute
inflammatory responses, which result in the pathogenesis of inflam-
matory disorders, failure of pathogen clearance and worsening sever-
ity [13]. In intestine, neutrophil accumulation and abscess formation
at the epithelial surface are pathological features of inflammatory dis-
ease processes including UC, infectious colitis and necrotizing entero-
colitis [14]. The pathological contributions from neutrophils are
essential during these inflammation, whereas only a few of the molec-
ular interactions related are known [15]. Current studies have found
that activated Sdc1 shedding in lung, liver and kidney of endotoxemic
mice was associated closely with the resolution of accumulated neu-
trophils by removing sequestered CXC chemokines, while in SDC1-
null mice, neutrophilic inflammation was exaggerated, leading to
organ damage and lethality [16]. In SDC1-deficient mice colitis
model, neutrophils acted increasing adhesion to endothelial cells and
intercellular adhesion molecule-1(ICAM-1), which increased leukocyte
influx leading to an overshooting inflammatory reaction, as well as
failing to resolve the leukocyte infiltrate and potentially increase leth-
ality [12]. In spite of these, interactions among SDC1, neutrophil
transmigration and inflammatory responses are still rarely investi-
gated, and the potential roles of SDC1 extracellular domain in inflam-
matory process of UC have not been fully explored.
In this study, we aimed to identify the role of epithelial-expressed
SDC1 in neutrophilic inflammation and neutrophil transmigration. The
potential role of SDC1 in pro-inflammatory cytokine secretion and
inflammatory pathway was elucidated in vitro and in vivo. The associ-
ation between SDC1 shedding and neutrophil transmigration in
intestinal cells unravels a novel mechanism underlying the contribu-
tion of SDC1 to intestinal inflammation, and suggests that the use of
SDC1 ectodomain could have a particular therapeutic impact on
intestinal neutrophilic inflammation.
Materials and methods
Reagents and antibodies
The RPMI-1640 or DMEM medium and fetal bovine serum (FBS) were
purchased from Gibco, Inc. (Carlsbad, CA, USA). Phorbol 12-myristate
13-acetate (PMA) and lipopolysaccharide (LPS) from Escherichia coli
(serotype 0111:B4) were obtained from Sigma-Aldrich (St. Louis, MO,
USA). Goat antimouse SDC1 antibody, and human tumour necrosis fac-
tor alpha (TNF-a, Cat. DTA00C), interleukin-1beta (IL-1b, Cat. DLB50),
cytokine-induced neutrophil chemoattractant ELISA kits (CINC-1, CXCL-
1, Cat. QC101) were all purchased from R&D Systems, Inc. (Min-
neapolis, MN, USA). NF-jB P65 (8242) and NF-jB p65 (3033) antibody
were purchased from Cell Signaling Technology Inc. (Danvers, MA,
USA). Mouse anti-human SDC1 antibody and CD15 antibody was pur-
chased from Santa Cruz Biotechnology Inc. (Dallas, TX ,USA) and
ZSGB-Bio Inc. (Beijing, China) respectively. Human Sdc1 ELISA kit was
purchased from Elabscience Biotechnology Co., Ltd (Cat. E-EL-H1298;
Wuhan, China).
Tissue samples
Formalin-fixed, paraffin-embedded tissue samples from 20 patients with
UC and 20 normal controls were randomly obtained on endoscopic
examination from the Department of Gastroenterology, Nanfang Hospital
during 2011–2012, and had been processed by routine clinical
histopathological methods. Definitive diagnosis of UC was established
by standard endoscopic, histological and clinical criteria [17]. The par-
tial Mayo score was determined previously as described and classified
into remission stage (less than two) and active stage(more than two)
[18]. Patients with septic complications, short bowel syndrome or can-
cer, and pregnant women were excluded. Their sociodemographic and
clinical data are summarized in Table 1.
Venous blood was collected after an overnight fast. Routine blood
tests were analysed soon. Serum was obtained by centrifugation at
1800 g for 10 min., and the aliquots of the serum were stored at
80°C until analysis. The study was carried out in accordance with the
institutional ethical guidelines and had been approved by the medical
ethics committee of Southern Medical University. Informed consent was
obtained from all patients.
Immunohistochemical analysis and evaluation
The immunohistochemical methods have been described previously
[19]. Sections were deparaffinized, rehydrated, quenched of endogenous
peroxidase, antigen retrieved and incubated with the indicated primary
antibodies diluted by 1:100 overnight at 4°C. After extensively washing,
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slides were incubated with a secondary reagent, developed with the
DAB reagent (ZSGB-Bio Inc, Beijing, China), counterstained with haema-
toxylin and mounted. Negative controls were incubated without antibody
or non-specific rat IgG at an equivalent protein concentration. The histo-
logical specimens were examined by two senior pathologists blinded to
the protocol. The score was determined according to the intensity of
staining independently, as ranked from grade 0 to 3: 0, less than 10%
of cells stained; 1, 10–50% of cells stained; 2, 50–75% of cells stained;
3, more than 75% of cells stained. For SDC1, only the membranes of
surface epithelial cells and glandular epithelium cells with staining were
scored. Meantime, tissue specimens were stained with haematoxylin
and eosin and classified as normal mucosa, mild, moderate or severe
enteritis (score 0–3), according to the proportion of sample crypt
cross-sections containing intraluminal or intra-epithelial neutrophils.
Construction of the SDC1 expression plasmid
A full-length mouse SDC1 cDNA corresponding to bases 1–3057 of
Genbank accession no. NM_011519.2 was amplified by PCR from a
normal intestinal cDNA library (extracted from normal newborn BALB/c
mouse). The primers for SDC1 were 50-GTGAAGCTTATGAGACGCG
CGGCGCTCTG-30 (forward) and 50-GTGGATCCTCAGGCGTAGAACTCCT
CCTGCTTG-30 (reverse). The PCR product was cloned into the
pcDNA3.0 vector (Invitrogen, Carlsbad, CA, USA) to create the
pcDNA3.0-wild-type SDC1 plasmid (wt-SDC1). A mutant form of SDC1
which stably anchored at cell surface in response to shaddase, such as
PMA and LPS, was constructed (cleavable-resistant SDC1 mutant, mut-
SDC1). Site-directed mutations at positions 243 and 244 (where the
cleavage site of SDC1 was first found) [20] were carried out by overlap
extension PCR using four specific primers: (i) 50-GTGAAGCTTATGA
GACGCGCGGCGCTCTG-30, (ii) 50-CTTCCTGTCCAAAAGGCTCTGCCAAG-
TACCTGTGGCTCCTTCGTCC-30, (iii) 50-GGAGCCACAGGTACTTGGCAGAGC
CTTTTGGACAGGAAGGAAGTGC-30, (iv) 50-GTGGATCCTCAGGCGTAGAACT
CCTCCTGCTTG-30. The orientation of the insert and the sequence of
cDNA were verified by sequencing, and the recombinant plasmids were
transfected into cells with use of Lipofectamine 2000 (Invitrogen, Carls-
bad, CA, USA) respectively.
Cell culture and treatments
The intestinal epithelial cell lines including HT29, SW620, SW480, LoVo,
HCT116, Caco-2 and IEC-6 were purchased from American Type Culture
Collection, and cultured routinely in RPMI 1640 (HT29, SW620, SW480,
LoVo and HCT116) or DMEM (Caco-2 and IEC-6) medium respectively,
supplemented with 10% or 20% FBS at 37°C in 5% CO2. Cultured or
transfected cells were incubated with 1 lM PMA for 15 min. or 1 lg/
ml LPS from E. coli for 24 hrs, then processed as follows.
Reverse transcription-PCR
Total RNA was extracted from cells using Trizol (Invitrogen, CA, USA).
RNA samples were subjected to RT using a First Strand cDNA Synthesis
Kit (Takara, Dalian, China). The primers used are listed in Table 2. PCR
Table 1 Baseline demographic and clinical features of the study population
UC
Healthy control
Active Remission
Patients 16 4 20
Gender(male/female) 8/6 3/3 11/9
Median age in years(IQR) 44.5 (28–52.5) 41 (25.25–53.25) 38.5 (29.75–49)
Median partial Mayo score(IQR) 8 (6.25–11) 0.5 (0–1.75)
Disease extent
Proctitis 3 1
Left-sided colitis 2 1
Extensive colitis 11 2
Medications
Treated patients (n) 13 4
5-ASA 13 4
Steroids 9 2
AZA 7 1
Anti-TNF-a agents 11 4
UC: ulcerative colitis; ASA: aminosalicylic acid; AZA: azathioprine; TNF-a: tumour necrosis factor alpha; IQR: interquartile range.
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was initiated by a 5-min. incubation at 94°C, and ended after a 10-min.
extension at 72°C, with 40 cycles for denaturation at 94°C for 30 sec.,
annealing at 60°C for 30 sec., and extension at 72°C for 1 min. using a
PCR kit (SBS Gene Tech Co., Beijing, China). GAPDH mRNA was ampli-
fied simultaneously as an internal control.
Western blot and dot-blot assay
To detect the expression of cell surface SDC1 and components of the
inflammatory pathway, cells were lysed in RIPA (Radio Immunoprecipi-
tation Assay) buffer with 1% PMSF, protease inhibitor cocktail and
phosphatase inhibitor. Protein was loaded onto an SDS-PAGE minigel
and transferred onto a PVDF membrane. The blot was probed with pri-
mary antibody (1:1000) at 4°C overnight, washed and incubated with
the appropriate HRP-conjugated secondary antibody. Signals were visu-
alized using ECL Substrates (Millipore, Boston, MA, USA). GAPDH was
used as an endogenous protein for normalization.
To detect the shed SDC1 ectodomain, cell culture supernatant was
applied to a ABS-Tween buffer (50 mM sodium acetate NaOAc, 150 mM
sodiurn chloride, 0.1% Tween20) moistened PVDF membrane under a
mild vacuum, in a dot-blot apparatus (Whatman, Maidstone, Kent, Eng-
land). After three washes with PBS buffer, the membrane was incubated
overnight in an anti-SDC1 antibody (1:1000) at 4°C, followed by incuba-
tion with secondary antibody, and was then exposed to ECL substrates.
Immunofluorescence assay
Cells were fixed in iced methanol for 10 min., blocked for 1 hr at room
temperature in PBS containing 5% bovine serum albumin, and incu-
bated at 4°C overnight with an anti-SDC1 antibody (1:100). Cells with-
out antibody incubation were used as control. After three washes, cells
were labelled with PE-conjugated IgG for 1 hr at room temperature,
stained with DAPI for 10 min., mounted on glass slides, and examined
with a fluorescence microscope.
ELISA
Concentrations of SDC1, TNF-a, IL-1b and CXCL-1 in the cell culture
supernatant or serum samples were determined by sandwich-type
ELISA, performed according to the manufacturer’s instructions. Absor-
bance was read at 450 nm, and the concentration was determined by
comparing their optical densities to a standard curve.
Isolation of neutrophils and migration assay
Five or two millilitres of venous blood from healthy people or from rats,
respectively, was drawn into heparin-containing collection tubes and
processed within 2 hrs. Neutrophils were isolated as described previ-
ously and cell viability were evaluated by trypan blue staining [21]. For
the migration assay, 0.5 9 106 neutrophils in 10% FBS medium were
added to the upper insert of each transwell polyester membrane filter
(6.5-mm-diameter inserts, 3.0-lm pore size; BD, NY, USA) and 500 ll
cell culture supernatant was collected from the epithelial cells at the
indicated time-point (when secretion of CXCL-1 was highest), and
added to the matched lower chamber. After 24 hrs incubation, non-
migrated cells were removed from the upper surface with a cotton
swab. Cells that had migrated to the lower membrane surface were
fixed in methanol and stained with 0.1% crystal violet, and cells in the
lower supernatant were counted by trypan blue staining. Migration rate
was calculated as a percentage of total neutrophils added to the upper
insert.
Dextran sodium sulphate-induced colitis models
Dextran sulphate sodium salt (DSS) (MW: 36,000–50,000 Da; MP
Biomedicals, Santa Ana, CA, USA) was used to induce colitis in mice,
as described previously [22]. A total of 40 male BALB/c mice (6–
8 weeks old, 20  2 g) were obtained from the Animal Center of
Southern Medical University, China. The experimental protocol was
Table 2 Primers used for PCR
Gene Forward primer Reverse primer
Human
TNF-a AAGTGGACCTTAGGCCTTCC AGCCTATTGTTCAGCTCCGT
IL-1b CAGGACAGTCAGCTCTCTCC ATGTGGGAGCGAATGACAGA
IL-8 GACCCAACCACAAATGCCAG CTGACCAGAAGAAGGAATGCC
IL-6 GTCTGTTGTAGGGTTGCCAG GGATATTCTCTTGGCCCTTGG
Rat*
TNF-a CAAAGGCGGAGATGAGACCC AGGCTTCTCCTTTGTGGTGAG
IL-1b TCCATTCCTGAGAGCCAAGC TTAGCATGCCTGCCCTGAAC
IL-6 CAGCTGATGCTGCCTATTGC GGACGCACTCACCTCTTGTT
GAPDH CACATCGCTCAGACACCATG TGACGGTGCCATGGAATTTG
*The mRNA level of IL-8 in IEC-6 cells was not determined because there is no orthologue for IL-8 gene in rat.
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approved by the Institutional Animal Care and Use Committee of South-
ern Medical University, China.
All animals were housed four per cage under specific pathogen-free
conditions (room temperature-controlled at 24  2°C with a relative
humidity of 60  5%, on a 12 hrs light/dark cycles) and fed ad lib with
standard rodent chow and fresh normal saline. After a 1-week quaran-
tine, mice were randomly divided into five treatment groups: fresh dis-
tilled water control, DSS, DSS plus vector, DSS plus wt-SDC1 and DSS
plus mut-SDC1. All mice, except for those in the control group, were
given 4% DSS for 6 days. On day 7, mice in the DSS plus vector, DSS
plus wt-SDC1 and DSS plus mut-SDC1 groups were given an intra-peri-
toneal injection of in vivo-jet PEI (Polyplus, Illkirch, France)-mediated
indicated DNA transfection twice (once every 3 days) respectively. The
DSS group was injected with PBS. The control group was given fresh
distilled water for drink and an injection of the same volume of PBS. All
mice were given fresh distilled water for drink for another 7 days, and
were killed on day 14.
During DSS colitis, the disease activity index (DAI) was determined
by scoring the extent of bw loss (ranking 0–4, 0: no weight loss; 1:
weight loss within 5%; 2: within 5–10%; 3: within 11–15%; 4: more
than 15%), stool hemoccult positivity or gross bleeding (0: normal; 2:
guiac; 4: gross bleeding), and stool consistency (0: normal; 2: loose; 4:
diarrhoea). The final DAI was equal to one-third of the combined score.
Histology of tissue from the colons, and mucosal expression of SDC1,
P65, p-P65 were studied by haematoxylin and eosin staining, immuno-
histochemistry or western blot respectively. The scores were all deter-
mined by an investigator who was blind to the experimental groups [7].
Blood was collected, and ELISA used to measure serum levels of TNF-a
and IL-1b.
Statistical analysis
All data from independent experiments were expressed as
mean  S.E.M, and were processed using SPSS 13.0 statistical soft-
ware (IBM, Armonk, NY, USA). Experiments were repeated at least twice
for assays. Student’s t-test (between two independent groups) and one-
way ANOVA with Duncan multiple range test (among multiple independent
groups) was used to compare differences in focused groups. Spear-
man’s correlation analysis was used to define associations. The level of
significance was defined as P < 0.05.
Results
Increased cellular SDC1 shedding and activated
inflammatory factors were observed in patients
with UC
In patients with UC, cellular SDC-1 shed from the cell surface was
significantly activated. Syndecan-1 expresses on the cellular mem-
brane of UC patients was lower than that of normal controls
(Fig. 1A). Syndecan-1 staining was present mainly in the membrane
in normal mucosa, whereas its expression in UC patients was either
barely detectable on cell membranes or mainly located in stromal
cells. Meanwhile, the expression of soluble SDC-1 in serum of UC
patients was almost three times higher than in normal controls
(P < 0.01, Fig. 1B), suggesting that the increased SDC-1 shedding
may because of the decrease in cell surface SDC-1 located in colon
mucosa.
Immunohistochemistry staining showed significantly positive
expression of P65, a canonical component of NF-jB pathway which
was detected in intestinal epithelium of UC patients, while staining of
P65 in normal mucosa was weak or absent (Fig. 1A). Parallelly,
serum levels of pro-inflammatory cytokines, TNF-a and IL-1b, were
also significantly higher in UC patients than in normal controls
(P < 0.01, Fig. 1C), same as CRP (P < 0.05, Fig. 1C), following a
similar pattern as SDC1.
Higher circulating neutrophils in UC patients
positively correlate with activated serum SDC1
Because inflammatory factors, such as TNF-a, IL-1b and NF-jB, are
reported to be involved in the recruitment of several cell types of leu-
cocyte [23], we tested whether the specific neutrophil subset, critical
in pathogenesis of UC [24], responds to this activation. Circulating
white blood cells and neutrophils were both elevated in UC patients in
active stage compared with those in either patients in remission stage
(P < 0.01, Fig. 1D) or normal controls (data not shown). Moreover, a
scatterplot revealed a significantly positive correlation between shed
SDC1 in serum and circulating neutrophil rate (R = 0.634, P < 0.01,
Fig. 1E). Otherwise, immunohistochemistry staining and haema-
toxylin and eosin staining showed a high level of CD15 in colitic
mucosa and intense inflammatory cell infiltration in lamina propria,
both demonstrated more neutrophil recruitment into the intestine of
UC patients (Fig. 1A).
Shed SDC1 from cell surface was accompanied
by activated inflammatory pathway and cytokine
secretion in HT29 cells
The SDC1 shedding from cell surface is induced by PMA, and
results in the appearance of the free SDC1 ectodomain in the med-
ium where the cells are growing [24]. Thus, we used PMA to treat
cultured cells and establish a cell model in which shed SDC1 is
activated. We first examined the SDC1 expression in six colonic
epithelial cell lines. Western blot showed that both HT29 and
SW480 had prominent SDC1 expression, while Caco-2 had much
lower SDC1 expression, therefore HT29 cells were selected as a
model here (Fig. 2A). Upon PMA stimulation, SDC1 on the cellular
membrane decreased (Fig. 2B) and soluble SDC1 shed into the cell
supernatant significantly increased detected by both dot blot and
ELISA assay (P < 0.01, Fig. 2C). Resembling the increased level of
shed SDC1, levels of secreted pro-inflammatory cytokines including
TNF-a, IL-1b, IL-6 and IL-8 were all elevated (P < 0.01, Fig. 2D).
Moreover, inflammation-associated NF-jB pathway including P65
and p-P65 were also activated in cells with activated SDC1 shed-
ding (Fig. 2E).
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Shed SDC1 from cell surface was accompanied
by increased CXCL-1 secretion and neutrophil
migration
Neutrophils are a vital component of the innate immune system, and
are the first leucocytes that were recruited to the inflammatory site;
migration of neutrophils is always preceded by generation of the
many chemotactic factors, among which the most important ones are
IL-8 and CXCL-1 [15]. Thus, we detected the level of CXCL-1 in
supernatants from HT29 cells treated by PMA. Enzyme-linked
immunosorbent assays showed that CXCL-1 secretion displayed a
similar pattern with shed soluble SDC1 upon PMA stimulation
(Fig. 2F), suggesting that PMA can induce both SDC1 shedding and
CXCL-1 secretion. Then, we collected the cell growth media to treat
neutrophils isolated from human venous blood, and found that migra-
tion of human neutrophils treated with the media from PMA-stimu-
lated cells (with higher level of IL-8 and CXCL-1) was significantly
higher than the media from untreated cells (P < 0.01, Fig. 2G).
Fig. 1 Levels of shed SDC1 and P65, secretion of TNF-a and IL-1b, as well as circulating neutrophil rate in ulcerative colitis patients. (A) Represen-
tative immunostaining of SDC1, P65 and CD15 in intestinal mucosa with overview (1009) and a magnification (4009). The right lane: haematoxylin
and eosin staining. (B) Levels of shed SDC1 in serum was detected by ELISA; n = 20. (C) Levels of secreted TNF-a (n = 20) and IL-1b (n = 20) in
serum were detected by ELISA; Circulating CRP was significantly higher in UC patients at active stage, n = 20. (D) Circulating white blood cells and
neutrophils were significantly higher in UC patients at active stage; n = 20. (E) Shed SDC1 in serum was positively correlated with circulating neu-
trophil rate (R = 0.634, P < 0.01). n = 20. *P < 0.05, **P < 0.01.
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Cell surface-anchored SDC1 inhibited
inflammatory pathway in Caco-2 cell
It is reported that PMA treatment alone might induce inflammation
despite the function of SDC1 [19]. Thus, to further obtain direct evi-
dence on the relationship between SDC1 and inflammation-related
factors, we establish a cell model in which no SDC1 shedding occurs
subsequent to PMA stimulation by transfecting a mutant form of mut-
SDC1 plasmid into intestinal epithelial cells. At 24 hrs post transfec-
tion, we found marked increases in the expression of cell surface
SDC1, both at the mRNA and protein levels, in Caco-2 cells trans-
fected with wt-SDC1 or mut-SDC1 plasmid, compared with the paren-
tal and vector-transfected cells (Fig. 3A). Conditioned growth media
was collected to measure levels of shed SDC1. After stimulation with
LPS, dramatic increases were detected in the soluble ectodomains of
SDC1 in the conditioned medium from wt-SDC1-transfected cells,
whereas shed SDC1 from mut-SDC1-transfected cells was signifi-
cantly suppressed (P < 0.01, Fig. 3B).
Lipopolysaccharide stimulation led to significant up-regulation
of TNF-a, IL-1b, IL-6 and IL-8 in Caco-2 cells. Transfection with
wt-SDC1 and mut-SDC1 led to down-regulation of these cytokines,
but the decrease was more notable in the mut-SDC1-transfected cells
(P < 0.01, Fig. 3C). The NF-jB pathway presented with induced
phosphorylation and activation in response to LPS; but the induced
activity was markedly less in cells transfected with mut-SDC1
(Fig. 3D). These data suggest that SDC1 negatively regulates the
pro-inflammatory cytokine secretion and inflammatory pathway acti-
vation, and this influence may be primarily dependent on the suppres-
sion of ectodomain shedding.
Cell surface-anchored SDC1 inhibited CXCL-1
secretion and neutrophil migration
Use the previous model, we examined whether levels of cell surface
SDC1 influence levels of CXCL-1, and thus affected the transmigration
of neutrophils. Following LPS stimulation, the levels of CXCL-1
started increasing in supernatants from Caco-2 cells, in a time-depen-
dent manner, followed by a slight decrease after 24 hrs. Syndecan-1
inhibited the secretion of CXCL-1, as seen in cells transfected with
Fig. 2 Shed SDC1 and inflammatory
responses induced by PMA in HT29 cells.
PMA was used to induce SDC1 shedding
in HT29 cells. (A) Levels of Sdc1 in six
intestinal epithelial cells were detected by
western blot. GAPDH was used as the
loading control. (B) Level of cell surface
SDC1 was detected by immunofluores-
cence. SDC1 (red), cell nucleus (blue),
original magnifications: 409. (C) Levels of
shed SDC1 in the cell culture supernatant
were detected by ELISA (upper) and dot
blot (lower). (D) Levels of secreted TNF-a,
IL-1b, IL-6 and IL-8 in the cell culture
supernatant were detected by PCR. (E)
Levels of P65 and phosphorylated P65
were detected by Western blot. (F) Secre-
tion of CXCL-1 was detected by ELISA.
(G) Neutrophils were isolated from human
venous blood, and their transmigration
was measured with use of transwell
inserts. Crystal violet staining was used to
observe the cell quantity change. Values
represent mean  S.E.M (n = 3),
*P < 0.05, **P < 0.01, based on t-test.
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wt-SDC1 or mut-SDC1; this inhibitory effect was especially greater in
the presence of cell surface anchored SDC1 (P < 0.01, Fig. 4A).
CXCL-1 levels were highest at 24 hrs after LPS stimulation;
thus we collected conditioned growth media at 24 hrs to treat neu-
trophils isolated from human venous blood using a transwell filter.
Migration of neutrophils treated with media from LPS-stimulated
cells was significantly higher than when the media was from
untreated cells. But this effect on migration was markedly inhibited
when neutrophils were treated with media from wt-SDC1- and
mut-SDC1-transfected cells, with media from mut-SDC1-transfected
Fig. 3 Cellular inflammatory responses induced by LPS was inhibited by cell surface-anchored SDC1 in Caco-2 cells. SDC1 shedding is blocked in
Caco-2 cells transfected with mut-SDC1 plasmid and LPS was used to induce inflammatory responses. (A) Protein (upper) and mRNA (lower) levels
of cell surface SDC1 were measured by western blot and PCR respectively. GAPDH was used as the loading control. (B) Levels of shed SDC1 in the
cell culture supernatant were detected by ELISA (left upper) and dot blot (left lower). Protein level of cell surface SDC1 upon LPS stimulation was
measured by immunofluorescence (right). SDC1 (red), cell nucleus (blue), original magnifications: 4009. (C) Cell surface-anchored SDC1 down-
regulated secretion of TNF-a, IL-1b, IL-6 and IL-8 in the cell culture supernatant detected by PCR. (D) Cell surface-anchored SDC1 inactivated NF-
jB pathway detected by Western blot. (E) Cell surface-anchored SDC1 alleviated impaired viability induced by LPS, but had no significant effect on
cell proliferation. Values represent mean  S.E.M (n = 3) and were analysed by Duncan’s multiple range test for multiple comparison in ANOVA
(**P < 0.01. # significance between wt-SDC1 and mut-SDC1, ##P < 0.01).
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cells (containing shed SDC1) mediating a more marked inhibition
(P < 0.05, Fig. 4B and C).
Cell surface-anchored SDC1 ameliorates colitis
activity, and mitigates the histological changes
in the colon during DSS-induced colitis
To further investigate the effects of SDC1 on intestinal inflammation
in vivo, we introduced the mouse model of DSS-induced colitis.
Immunohistochemical staining showed that DNA transfection in vivo
successfully enhanced SDC1 expression in colon mucosa in the DSS
plus wt-SDC1 and DSS plus mut-SDC1 groups, especially in mut-
SDC1-treated group, since partial SDC1 was cut from the epithelial by
DSS in wt-SDC1-treated group (Fig. 5, the bottom row). Histological
images of the colon from the DSS-treated mice showed destruction
of the epithelial architecture, impaired crypts and glands, multifocal
shallow ulcers and intense inflammatory cell infiltration in the lamina
propria; however, fewer of these lesions were seen in the SDC1-trans-
fected group than in vector-transfected mice (Fig. 5, the top row).
The control mice without DSS treatment had normal bw, colons and
stools. Diarrhoea and guaiac positivity was noted in the DSS and the
DSS plus vector group, starting on day 3 following DSS treatment;
gross bleeding was detected starting on day 6. Weight loss, shorter
colons and gross ulceration was also recorded. In contrast, the colitis
symptoms were substantially relieved in the DSS plus wt-SDC1 and
DSS plus mut-SDC1 groups. Consistently, DAI scores were signifi-
cantly higher in mice 6 days after DSS treatment; while the increased
score was suppressed in DSS plus wt-SDC1 and DSS plus mut-SDC1
groups (P < 0.05, Fig. 6A). Moreover, the improved symptoms of
colitis, and the reduced DAI scores were more marked in the DSS
plus mut-SDC1 group than in the DSS plus wt-SDC1group. These
results indicate that SDC1 mitigates disease activity as well as the tis-
sue damage associated with DSS-induced colitis, and suppression of
ectodomain shedding further improves these effects.
Cell surface-anchored SDC1 inhibited
inflammatory pathway activation and cytokine
secretion during DSS-induced colitis
Higher levels of P65 and p-P65 were observed in DSS-induced
inflammatory tissues compared with normal tissues, but this increase
was markedly attenuated in tissues with supplemented Sdc1 by DNA
transfection (Fig. 6B). Similarly, serum levels of TNF-a and IL-1b
were significantly up-regulated after DSS administration, compared
Fig. 4 Secreted CXCL-1 induced by LPS and sequent neutrophil transmigration was inhibited by cell surface-anchored SDC1 in Caco-2 cells. LPS
was use to induce secretions of CXCL-1, and expression of CXCL-1 was assessed by ELISA. (A) The level of secreted CXCL-1 was down-regulated
by Sdc1. (B and C) Cell culture supernatants containing high concentrations of CXCL-1 were used to induce migration of human neutrophils. CXCL-
1 secretion promoted migration of neutrophils; this promoting effect was diminished when cells were transfected with mut-SDC1. The transmigra-
tion was measured with use of transwell inserts, crystal violet staining was used to observe the cell quantity change. Values represent
mean  S.E.M (n = 3) and were analysed by Duncan’s multiple range test for multiple comparison in ANOVA (*P < 0.05, **P < 0.01. #significance
between wt-SDC1 and mut-SDC1, #P < 0.05).
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with the control group. The increases in secretion were lessened
when wt-SDC1 transfection or mut-SDC1 transfection was introduced
(P < 0.05, Fig. 6C and D). Moreover, for IL-1b, the reductive extents
were more notable in the DSS plus mut-SDC1 group (P < 0.05,
Fig. 6D). These data indicate that SDC1 negatively regulates the pro-
inflammatory cytokine secretion, and this influence may be primarily
dependent on the suppression of ectodomain shedding.
Discussion
Our study describes a mechanism in which three components, a com-
mon disease (UC), a cell-bound proteoglycan with shedding
-resistance (SDC1) and an inflammatory response (neutrophil
transmigration), act coordinately to function. We successfully con-
structed a model in which SDC1 is not shed off from the cell surface
upon PMA stimuli, which will facilitate further study of this topic. And
the results document a significant correlation between SDC1 shedding
and the regulation of inflammation in colitis patients’ samples and
intestinal epithelial cells. It is also showed that SDC1, especially when
anchored on the cell surface, inactivates several canonical inflammatory
pathways, down-regulates pro-inflammatory cytokines and inhibits neu-
trophil migration induced by CXCL-1. These results were further con-
firmed in a mouse model of DSS-induced colitis. To sum up, these
findings indicate that the cell surface-anchored SDC1 alleviates the
inflammatory response by inhibiting inflammatory pathways (such as
NF-jB) and pro-inflammatory cytokines (such as TNF-a) to a certain
extent.
Fig. 5 Effects of cell surface SDC1 on histology of colitis in mice. Immunohistochemical staining of mucosal SDC1 (lower) and haematoxylin and
eosin staining (upper) in sections of mouse intestine. Original magnifications: 2009.
Fig. 6 Effects of cell surface SDC1 on
activity of colitis in mice. (A) DAI value
during the course of DSS-induced colitis.
(B) Activities of NF-jB pathway in colonic
mucosa of mice. Secreted TNF-a (C) and
IL-1b (D) in serum of mice. Values repre-
sent mean  S.E.M (n = 3) and were
analysed by Duncan’s multiple range test
for multiple comparison in ANOVA
(**P < 0.01. # significance between wt-
SDC1 and mut-SDC1, ##P < 0.01).
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These above results are consistent with those found in patients
with Crohn’s disease (CD), which demonstrated the decreased
levels of SDC1 in the intestinal mucosa and the increased levels of
its ectodomain in the serum [25]. However, our results are differ-
ent from a recent study performed by Israeli researchers, which
showed elevated levels of soluble SDC-1 in CD patients, but no dif-
ference between UC patients and healthy controls [26]. The causes
of the differentiated outcomes between Israeli patients and our
study were unknown yet. Both studies recruited a small number of
patients, and the inconsistency of disease activity, even race, prob-
ably had some effects.
The intestine is a unique tissue, where an elaborate and har-
monious balance is maintained that has often been referred to as
a state of controlled inflammation. In the event where this balance
is lost, diseases, such as inflammatory bowel disease (IBD), coe-
liac disease or food allergy, would come up [27]. Recently, accu-
mulated evidence highlights the significance of SDC1 in this
balance. Syndecan-1 is essential in maintaining intestinal epithelial
barrier function, specific loss of SDC1 might wreck the natural
barrier, causing far more susceptibility to protein-loss enteropathy
and bacterial translocation [7, 28]. Recent studies have also
showed the interactions between SDC1 and tight junction protein.
Syndecan-1 co-expresses with Claudin-2, ZO-1 and Occludin
decrease synchronously with SDC1 destruction [29, 30]. Besides,
pathological destrction of SDC1 would disrupt internal immune
system. We have confirmed the protective role of SDC1 in intesti-
nal inflammatory responses. Previous studies also showed Pseu-
domonas aeruginosa activated the ectodomain shedding of SDC1,
but such SDC1 shedding promotes P. aeruginosa pathogenesis in
mouse models of lung and burned skin infection [31]. It is
well-known that CXCL-1 could induce inflammatory events via
neutrophil transmigration [32]. Syndecan-1 also contributes to
neutrophil chemotaxis: shed and exogenous SDC1 ectodomain
induces neutrophil chemotaxis, inhibits epithelial wound healing
and promotes fibrogenesis in a mouse model of idiopathic pul-
monary fibrosis [33]. In mouse S. aureus corneal infection, the
ectodomain of SDC1 could inhibit S. aureus killing by antimicrobial
factors secreted by degranulated neutrophils, but does not affect
intracellular phagocytic killing by neutrophils, indicating that SDC1
has a close association with the factors secreted by neutrophils
[34]. Syndecan-1-null endotoxemic mice showed a deficiency in
the removal of CXCL-1 in tissues, conversely, SDC1 shedding
facilitated the clearance of CXCL-1 and resolution of neutrophilic
inflammation in an HS-dependent manner [16]. However, the rela-
tionship between SDC1 and CXCL-1-dependent neutrophil migra-
tion in intestinal inflammation had rarely been studied. Our
findings show that high levels of CXCL-1 recruit additional neu-
trophils and aggravate intestinal injury; this inflammatory response
can be abolished by SDC1, especially by its cell-bound ectodo-
main. When SDC1 shedding was suppressed, CXCL-1 secreted by
intestinal cells would significantly down-regulate and neutrophil
migration induced by conditioned growth media from these cells
also decreased. Moreover, these reductive extents are paralleled
with inactivation of NF-jB pathway and down-regulation of cytoki-
nes including TNF-a, IL-1b, IL-6 and IL-8.
Pathways such as NF-jB is recognized as critical regulators of
epithelial tissue homoeostasis and pathogenesis of inflammatory
diseases. Mucosal inflammation in patients with IBD, and in experi-
mental models of intestinal inflammation, is accompanied by ele-
vated levels of activated members of the NF-jB family, particularly
P65, P50 and c-Rel [35, 36]. And deletion of P65 attenuated LPS-
induced cytokine production, CCL11 expression in myeloid cells, as
well as inflammation and histopathology in mice [37]. In response
to LPS or DSS-induced SDC1 shedding, intestinal epithelial cells
showed P65 and phosphorylated P65, activated NF-jB. More
importantly, when its ectodomain shedding was inhibited, the
anchored SDC1 significantly attenuated these inflammatory effects.
Furthermore, we extended this network by showing the syn-
chronously induction of pro-inflammatory cytokines, including TNF-
a, IL-1b, IL-6 and IL-8.
The inflammation-associated network involves various factors
which interact with each other to form a complicated feedback loop
to function. For example, TNF-a, IL-1b, IL-6, IL-8 and CCR2 are
believed to be target genes of NF-jB through DNA-binding to the
corresponding promoter [38, 39]. Otherwise, TNF-a and IL-1b were
highly pro-inflammatory agents, accelerating NF-jB activation
directly via their ability to induce expression of IL-6 [40, 41]. Fur-
thermore, NF-kB/p65 interacts with Stat3. Stat3 up-regulated NF-jB
nuclear retention and enhanced NF-jB/P65 acetylation via serine
and tyrosine phosphorylation as well as the DNA-binding domain of
Stat3 [42]. Our results are in agreement with these previous find-
ings, although the signalling crosstalk within the cell surface SDC1-
associated complex is not clearly elucidated. Thus, further investi-
gation is needed.
The shedding of SDC1 ectomain and neutrophil transmigration in
UC might provide a new rationale for disease incidence and therapeu-
tic approach. More attention should be paid to investigate their practi-
cal clinical values. Our group has already confirmed the protective
role of low-molecular weight heparin, which is an analogue of SDC1
and can inhibit SDC1 shedding and consequently alleviate inflamma-
tion in DSS-induced mice colitis [43]. In accordance with results of
small trials which heparins benefits the SDC1 integrity in active gluco-
corticosteroid refractory in IBD [44, 45]. However, patients should
take a risk of possible adverse events such as serious bleeding. So a
modified heparin or sulphated oligosaccharide may be a breakthrough
of clinical application [46, 47].
In conclusion, we have found a protective role of SDC1 anchored
on the cell surface in inhibiting intestinal inflammation and neutrophil
transmigration. This observation indicates the potential value and
important insights of the therapeutic use of SDC1 for improving
intestinal inflammation. Suppression of SDC1 shedding in intestinal
epithelial cells plays an anti-inflammatory role, ameliorates colitis and
thus is helpful for this disorder treatment.
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